



Call for Expression of Interest

Local Partnerships for Precision Medicine

Introduction

Personalized and Precision Medicine (PM) can transform lives, but its potential benefits have not yet been fully realized. Patients' abilities to access precision medicine is not the same from one region or country to another. From Testing to Targeted Treatment Program (FT3) is a non-profit multi-stakeholder collaborative program that aims to unify, accelerate and build on existing efforts to make precision medicine a reality for all patients who could benefit from it.

Pilot opportunity

The "local partnerships for precision medicine" pilot program builds on the experiences of the global precision medicine community to increase access to PM for patients who could benefit from it. The objective of the pilots is to gather learnings, barriers to access, and best practices, and to share these learnings back with the wider PM community. The global community will support and share co-created tools for greater accessibility of precision medicine at national levels.

The pilot program aims to include 3-4 countries in total, starting with lung cancer. Pilots are expected to convene a group of different stakeholders (patients, healthcare professionals, industry, decision-makers). Following the principles of collaborative leadership, stakeholders will co-decide the priorities, scope, and shared objectives.

Why pilot with FT3?

- Benefit from global best practices and learnings identified by a multi-stakeholder group of experts
- Benefit from direct access to a multistakeholder expert network
- Improve the patient experience and patient outcomes in your focus area
- Share your experiences and learnings with the global Precision Medicine community
- Benefit from support to adapt, translate and customize resources
- Build visibility for your organization and work

Eligibility criteria

We are inviting expressions of interest from local champions of precision medicine or potential advocates of all parts of the world, including but not limited to: South Africa, Argentina, Mexico, Brazil, Australia, Taiwan, Japan, Korea, New Zealand, India, Egypt, Lebanon, Germany, France, Ireland, Italy, and in Eastern Europe. Proposed selection criteria include:

- Diversity of countries (continent, high, middle, low-income countries)
- Health system finance model
- Capacity and network available
- Language (ability to share lessons in English, opportunity to translate tools to other languages, capacity to translate information to local stakeholders)
- Levels of PM access and needs
- Access to the patient community (availability of registries, patient database, network)

How to apply?

Interested organizations and patient groups are invited to share their interest, contextual background and needs. Please apply by sending an email to lidewij@thesynergist.org by **August 22, 2022**. Please include in your email a brief summary of:

- your motivation to participate in the pilot program
- the local context (healthcare system, level of access to PM, challenges, needs)
- capacity and network availability
- language proficiency in English and other languages
- contact details

More information?

Join the FT3 pre-conference session at WCLC in Vienna on **Saturday, August 6th from 14:30 - 16:30 CET** to learn more about this pilot opportunity and help shape the pilot program. Register by email: lidewij@thesynergist.org.

More details about the pilot program can be found [here](#).

Website: Fromtestingtotargetedtreatments.org